Subscribe to RSS
DOI: 10.1055/s-2004-825697
Perioperative Gerinnungsstörungen
Perioperative Coagulation DisordersPublication History
Publication Date:
26 July 2004 (online)
Weiterbildungsziele In diesem Beitrag sollen folgende Weiterbildungsziele vermittelt werden: Antikoagulatorische Medikamente einschließlich der neueren Thrombozytenaggregationshemmer und Thrombininhibitoren Zeitliche Sicherheitsabstände bei antikoagulatorischer Medikation Physiologie der Gerinnungsaktivierung und -inhibierung Klinische Differenzierung statischer und dynamischer Gerinnungsstörungen Interpretation globaler Laborwerte Therapieoptionen und Indikationen für Gerinnungspräparate
Literatur
- 1 Latzka R, Koscielny J, Pruß A, Kiesewetter H. Klinischer Einsatz von Desmopressin und Antifibrinolytika. Anästh Intensivmed. 1999; 40 548-553
- 2 McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clinic North Am. 2001; 85 1277-1310
- 3 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997; 336 1506-1511
- 4 Robinson K L, Marasco S F, Street A M. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part one: bleeding and anticoagulation issues. Heart, Lung and Circulation. 2001; 10 142-153
- 5 Pastakia K B, Terle D, Prodouz K N. Penicillin-induced dysfunction of platelet membran glycoproteins. J Lab Clin Med. 1993; 121 546-554
- 6 Burroughs S F, Johnson G J. Beta-lactam antibiotic-induced platelet dysfunction: evidence of irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood. 1990; 75 1473-1480
- 7 Cazzola M, Matera M G, Santangelo G, Lampa E, Angrisani M, Loffreda A, Rossi F. Effects of some cephalosporins and teicoplanin on platelet aggregation. Int J Clin Pharmacol Res. 1993; 13 69-73
- 8 Opal S M, Kessler C M, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002; 30 (suppl) S325-S331
- 9 Hirsh J, Warkentin T E, Shaughnessy S G, Anand S S, Halperin J L, Raschke R, Granger C, Ohman E M, Dalen J E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119 Suppl 64S-94S
- 10 Greinacher A. Antikoagulation bei HIT II. Wann therapeutisch - wann prophylaktisch?. Anästhesiol Intensivmed Notfallmed Schmerzther. 2002; 37 Suppl 1 3-7
- 11 Gerlach R, Scheuer T, Beck J, Woszczyk A, Seifert V, Raabe A. Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study. Neurosurgery. 2003; 53 1028-1034
- 12 Roberts H R, Monroe D M, Escobar M A. Current concepts of hemostasis. Anesthesiology. 2004; 100 722-730
- 13 Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, Ostergaard P B. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin): An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis. 1994; 5 795-803
- 14 Gibbs N M, Weightman W M, Thackray N M, Michalopoulos N, Weidmann C. The effects of recent aspirin ingestion on platelet function in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2001; 15 55-59
- 15 Schafer A. effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995; 35 209-219
- 16 Tuman K J, McCarthy R J, O'Connor C J, McCarthy W E, Ivankovich A D. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg. 1996; 83 1178-1184
- 17 Kozek-Langenecker S A. Lokoregionalanästhesie und Blutgerinnung. Behandlung mit Thrombozytenfunktionshemmern. Anaesthesist. 2003; 52 549-562
- 18 Leese P, Hubbard R, Karim A, Isakson P C, Yu S S, Geis G S. Effects of celcoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000; 40 124-132
- 19 Gajraj N M. Cyclooxygenase-2 inhibitors. Anesth Analg. 2003; 96 1720-1738
- 20 Gogarten W, van Aken H, Büttner J, Riess H, Wulf H, Buerkle H. Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation. Anaesth Intensivmedizin. 2003; 44 218-230
- 21 Kövesi T, Royston D. Is there a bleeding problem with platelet-active drugs?. Br J Anaesth. 2002; 88 159-163
- 22 Chun R, Orser B A, Madan M. Platelet glycoprotein IIb/IIIa inhibitors: overview and implications for the anaesthesiologist. Anesth Analg. 2002; 95 879-888
- 23 Calenda E, Papion H, Borg J Y, Menguy E, Delaunay T, Watelet J, Testart J, Winkler C. Correction of bleeding time after administration of desmopressin in a woman treated with ticlopidine. Presse Med 1988 Nov. 12; 17 2143
- 24 Wilde M, Markham A. Danaparoid: A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997; 54 903-924
- 25 Lipp H P. Fondaparinux - ein synthetischer Faktor-Xa-Inhibitor. Krankenhauspharmazie. 2002; 23 141-148
- 26 Eriksson B I, Bergqvist D, Kälebo P, Dahl O E, Lindbratt S, Bylock A, Frison L, Eriksson U G, Welin L, Gustafsson D. Ximelagatran and megalatran compared with dalteparin for the prevention of venous thromboembolism after total hip or knee replacement. The METHRO II randomised trial. Lancet. 2002; 360 1441-1447
- 27 Gustafsson D, Nyström J, Carlsson S. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption, biochemical and pharmacodynamic effects. Thromb Res. 2001; 101 171-181
- 28 Johansson L C, Frison L, Logren U, Fager G, Gustafsson D, Eriksson U G. Influence of the age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet. 2003; 42 382-392
- 29 Pindur G, Ziegeler S, Kleinschmidt S. Melagatran und Ximelagatran. Pharmakologische Eigenschaften und anästhesiologische Aspekte. Anaesthesist. 2003; 52 1171-1175
- 30 Pravinkumar E, Webster N R. HIT/HITT and alternative anticoagulation: current concepts. Brit J Anaesth. 2003; 90 676-685
- 31 Ang-Lee M K, Moss J, Yuan C S. Herbal medicines and perioperativen care. JAMA. 2001; 286 208-216
- 32 Cheng B, Hung C T, Chiu W. Herbal medicine and anaesthesia. HKMJ. 2002; 8 123-130
- 33 Smith P F, Maclennan K, Darlington C L. The neuroprotective properties of the Gingko biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol. 1996; 50 131-139
- 34 German K, Kumar U, Blackford H N. Garlic and the risk of TURP bleeding. Br J Urol. 1995; 76 518
- 35 Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Med Hypotheses. 1986; 20 271-278
- 36 Yu C M, Chan J C, Sanderson J E. Chinese herbs and warfarin potentiation by „danshen”. J Intern med. 1997; 241 337-339
- 37 Page R L 2nd , Lawrence J D. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999; 19 870-876
- 38 Janetzky K, Morreale A P. Probable interactions between warfarin and ginseng. Am J Health Syst Pharm. 1997; 54 692-693
- 39 Bone R C. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med. 1992; 152 1381-1389
-
40 Holmsen H.
Biochemistry and function of platelets. Composition of platelets. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (Hrsg) Hematology. New York; McGraw Hill 1991: 1182-1200 - 41 Ehrman M E, Jaffe E A. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid - induced shape change and procoagulant activity. Prostaglandins. 1980; 20 1103-1116
- 42 Osterud B, Rapaport S I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 1977; 74 5260-5264
- 43 Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. J Biol Chem. 1980; 255 5703-5707
- 44 Edwards E L, Rickles F R. The role of leucocytes in the activation of blood coagulation. Semin Hematol. 1992; 29 202-212
- 45 Archipoff G, Beretz A, Freyssinet J M. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J. 1991; 273 679-684
- 46 Stern E M, Esposito C, Gerlach H, Gerlach M, Ryan J, Handley D, Nawroth P. Endothelium and regulation of coagulation. Diabetes Care. 1991; 14 160-166
- 47 Okajima K, Wang Y P, Okabe H, Inoue M, Takatsuki K. Role of leucocytes in the activation of intravascular coagulation in patients with septicemia. Am J Hematol. 1991; 36 265-271
- 48 Altieri D C, Morrissey J H, Edgington T S. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA. 1988; 85 7462-7466
- 49 Lentz S R, Tsiang M, Sadler J E. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood. 1991; 77 542-550
- 50 Moore K L, Andreoli S P, Esmon N L, Esmon C T, Bang N U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987; 79 124-130
- 51 Sakata Y, Curriden S, Lawrence D, Griffin J H, Loskutoff D J. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA. 1985; 82 1121-1125
-
52 Mann K G.
Membrane-bound enzyme complexes in blood coagulation. In: Spaet TH (Hrg) Progress in Hemostasis and Thrombosis. New York; Grune & Stratton 1994: 1-23 - 53 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III - dependent but not thrombin - dependent prostacyclin production in human endothelial cells. Thromb Res. 1990; 59 895-904
- 54 Vane J R, Änggard E E, Botting R M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990; 323 27-36
- 55 Walker F J, Fay P J. Regulation of blood coagulation by the protein C system. FASEB J. 1992; 6 2561-2567
-
56 Scherer R.
Gerinnung. In: Kochs E, Krier C, Buzello W, Adams HA (Hrsg) Anästhesiologie. 1. Aufl. Stuttgart; Thieme 2001: 143-149 -
57 Scherer R.
Plasmatische Gerinnungsstörungen mit Blutungsneigung. In: Van Aken, Reinhart K, Zimpfer M (Hrsg) Intensivmedizin. 1. Aufl. Stuttgart; Thieme 2001: 589-595 - 58 Scherer R U, Spangenberg P. Procoagulant activity in patients with isolated severe head trauma. Crit Care Med. 1998; 26 49-156
- 59 Pivalizza E G. Perioperative use of the thrombelastograph in patients with inherited bleeding disorders. J Clin Anesth. 2003; 15 366-370
- 60 Leslie K, Sessler D I. Perioperative hypothermia in the high-risk surgical patient. Best Pract Res Clin Anaesthesiol. 2003; 17 485-498
- 61 Baudo F, de Gasperi A, de Cataldo F. et al . Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res. 1992; 68 409-416
- 62 Langley P G, Hughes R D, Forbes A. et al . Controlled trial of antithrombin III supplementation in ful-minant hepatic failure. J Hepatol. 1993; 17 326-331
- 63 Schipper H G, Ten Cate J W. Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol. 1982; 52 25-33
- 64 Lechner K, Kyrle P A. Antithrombin III concentrates - are they clinically useful?. Thromb Haemostas. 1995; 73 340-348
- 65 Heinemann H, Schramm W, Hoffmann P, Lierz P. Multiorganversagen nach Gabe von PPSB beim isolierten Faktor VII-Mangel. Anästh Intensivmed. 1993; 34 130-133
- 66 Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnoses. Crit Care Med. 1980; 28 1777-1780
- 67 Schroeder S, Wichers M, Lier H. Diagnostik und Therapie von komplexen Gerinnungsstörungen in der operativen Intensivmedizin. Anaesth Intensivmedizin. 2003; 44 668-679
- 68 Scherer R, Paar D, Stöcker L, Kox W. Diagnose und Therapie pathologischer Gerinnungsaktivierungen. Anästhesist. 1994; 43 347-354
- 69 Arbeitsgemeinschaft der Bundesärztekammer. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 2. Aufl. Köln; Deutscher Ärzteverlag Köln 2001
- 70 König H, Hanker-Dusel C, Eich S, Grundmann C, Seitz R. The thrombogenetic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause. Thromb Haemost. 2003; 90 Suppl 1 S16-S48
- 71 Scherer R U. Hämostaseologische Aspekte des perioperativen Blutmanagements. Zentralbl Chir. 2003; 128 473-480
- 72 Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke. 2002; 33 1618-1623
- 73 Hoffman M, Monroe III D M. A cell-based model of hemostasis. Thromb Haemost. 2001; 85 958-965
- 74 Heuer L, Blumenberg D. Rekombinanter Faktor VIIa. Ein Überblick über aktuelle und mögliche zukünftige Indikationen. Anaesthesist. 2002; 51 388-399
- 75 Monroe D M, Hoffmann M, Oliver J A, Roberts H R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997; 99 542-547
- 76 Mannucci P M. Hemostatic drugs. N Engl J Med. 1998; 339 245-253
- 77 Levi M, Cromheecke M E, de Jonge E, Prins M H, de Mol B J, Briet E, Buller H R. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999; 354 1940-1947
- 78 Ozal E, Kuralay E, Bingol H, Cingoz F, Ceylan S, Tatar H. Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?. J Thorac Cardiovasc Surg. 2002; 123 539-543
- 79 Scherer R, Ostermann H, Forst H, Eckart J. Die postoperative Blutung. Anaesthesiologie Intensivmedizin. 1999; 11 786-788
Prof. Dr. med. R. U. Scherer
Zentrale Abteilung für Anästhesiologie und Intensivmedizin
Evangelisches und Johanniter Klinikum Duisburg/Dinslaken/Oberhausen gGmbH
Fahrner Straße 133 - 135
47169 Duisburg
Email: ralf.scherer@ejk.de